Randomised, Controlled, Open-Labelled, Multi-Centre Comparison of Thalidomide Versus High-Dose Dexamethasone for the Treatment of Relapsed and/or Refractory Multiple Myeloma.

Trial Profile

Randomised, Controlled, Open-Labelled, Multi-Centre Comparison of Thalidomide Versus High-Dose Dexamethasone for the Treatment of Relapsed and/or Refractory Multiple Myeloma.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Dexamethasone; Thalidomide
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms OPTIMUM
  • Sponsors Celgene Corporation; Pharmion Corporation
  • Most Recent Events

    • 01 Dec 2011 Primary endpoint 'Time-to-disease-progression' has not been met.
    • 29 Sep 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 29 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top